| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Animal Protocol |
A pharmacokinetic study was conducted in rats.
Male Wistar rats were fasted for 12 hours with free access to water prior to the experiment. Each rat was orally administered a Rhizoma Alismatis extract at a dose of 18 g/kg (calculated by crude drug weight). The extract was prepared by refluxing the crude drug with 95% ethanol and then dissolving the residue in an aqueous solution containing 0.5% sodium carboxymethylcellulose (CMC-Na). The final extract concentration was 1.5 g/mL (equivalent to crude drug), containing 0.5 mg/g Alisol A and 0.4 mg/g Alisol A 24-acetate. Blood samples (0.3 mL) were collected from the oculi chorioideae vein at predetermined time points (0, 0.08, 0.17, 0.33, 0.75, 1, 1.5, 2, 4, 6, 7, 8, 9, 10, 12, 16, and 24 hours) post-dose. The samples were placed in heparinized tubes and centrifuged to separate plasma. The plasma samples were stored at -20 °C until analysis. [1] |
|---|---|
| ADME/Pharmacokinetics |
This study established and validated a sensitive liquid chromatography-mass spectrometry (LC-MS) method for the simultaneous determination of alisol A and alisol A 24-acetate in rat plasma. The limits of quantitation (LLOQ) for both analytes were 10 ng/mL. The average recovery rate of alisol A 24-acetate from rat plasma was higher than 72.4%. The analyte exhibited good stability in rat plasma after three freeze-thaw cycles, 24 hours at room temperature, and 30 days at -20°C. Following oral administration of the alisol extract to rats, the concentration-time curve of alisol A 24-acetate showed a significant bimodal distribution. The pharmacokinetic parameters (mean ± standard deviation) of alismolide A 24-acetate are as follows: terminal half-life (T1/2) = 2.9 ± 0.9 h, maximum plasma concentration (Cmax) = 233.1 ± 55.4 μg/L, time to peak concentration (Tmax) = 9.2 ± 1.0 h, area under the concentration-time curve from 0 to 24 hours (AUC0–24h) = 1820 ± 464 μg·h/L, and area under the curve extrapolated to infinity (AUC0–∞) = 1874 ± 450 μg·h/L. The bimodal phenomenon may be attributed to the interconversion between related prosterane triterpenes in the extract (e.g., alissol B 23-acetate or alissol B 11,23-diacetate may be converted to alissol A 24-acetate), variability in gastrointestinal absorption, or enterohepatic circulation. [1]
|
| References |
|
| Additional Infomation |
Alisma orientalis has been reported to contain 24-acetic acid aliquot, and relevant data are available.
24-acetic acid aliquot is a major prosterane triterpenoid compound isolated from the traditional Chinese medicine Alisma orientalis (dried rhizome of Alisma orientalis). It has been reported to have diuretic, anti-inflammatory and cholesterol-lowering effects. The liquid chromatography-mass spectrometry method established in this study is the first to report the simultaneous determination of 24-acetic acid aliquot and 24-acetic acid aliquot in rat plasma after oral administration of Alisma orientalis extract. [1] Alismaol A 24-acetic acid ester is a major prosterane triterpenoid compound isolated from the traditional Chinese medicine Alisma orientalis. This compound is unstable in a variety of solvents. In protic solvents (e.g. methanol, ethanol), Alismaol A 24-acetic acid ester undergoes rapid acetyl migration to convert to its isomer, aliquot A 23-acetic acid ester. The conversion rate in protic solvents is faster than in aprotic solvents (e.g., acetone, acetonitrile, ethyl acetate, chloroform). When stored in methanol for a long period (e.g., more than 14 days), alisol A 24-acetate and alisol A 23-acetate undergo further deacetylation to generate alisol A. Single-crystal X-ray diffraction structure The structure of Alisol A 24-acetate has been determined and its configuration has been confirmed. The A and B rings are in a torsion boat conformation, the C ring is in a chair conformation, and the D ring is in an envelope conformation. The junctions of the A/B rings and the B/C rings are trans-connected. This study reports for the first time the structural interconversion between Alisol A 24-acetate, Alisol A 23-acetate and Alisol A, and resolves for the first time the single-crystal X-ray diffraction structure of Alisol A 24-acetate. [2] |
| Molecular Formula |
C32H52O6
|
|---|---|
| Molecular Weight |
532.7517
|
| Exact Mass |
532.376
|
| CAS # |
18674-16-3
|
| Related CAS # |
Alisol A;19885-10-0
|
| PubChem CID |
76336194
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
641.1±55.0 °C at 760 mmHg
|
| Melting Point |
194-196 ºC
|
| Flash Point |
196.5±25.0 °C
|
| Vapour Pressure |
0.0±4.3 mmHg at 25°C
|
| Index of Refraction |
1.547
|
| LogP |
5.27
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
38
|
| Complexity |
1010
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
C[C@H](C[C@@H]([C@H](C(C)(C)O)OC(=O)C)O)C1=C2C[C@@H]([C@H]3[C@]4(CCC(=O)C([C@@H]4CC[C@@]3([C@]2(CC1)C)C)(C)C)C)O
|
| InChi Key |
WXHUQVMHWUQNTG-JSWHPQHOSA-N
|
| InChi Code |
InChI=1S/C32H52O6/c1-18(16-23(35)27(29(5,6)37)38-19(2)33)20-10-14-31(8)21(20)17-22(34)26-30(7)13-12-25(36)28(3,4)24(30)11-15-32(26,31)9/h18,22-24,26-27,34-35,37H,10-17H2,1-9H3/t18-,22+,23+,24+,26+,27-,30+,31+,32+/m1/s1
|
| Chemical Name |
[(3R,4S,6R)-2,4-dihydroxy-6-[(5R,8S,9S,10S,11S,14R)-11-hydroxy-4,4,8,10,14-pentamethyl-3-oxo-1,2,5,6,7,9,11,12,15,16-decahydrocyclopenta[a]phenanthren-17-yl]-2-methylheptan-3-yl] acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 50 mg/mL (~93.85 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 3 mg/mL (5.63 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 30.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 3 mg/mL (5.63 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 30.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8771 mL | 9.3853 mL | 18.7705 mL | |
| 5 mM | 0.3754 mL | 1.8771 mL | 3.7541 mL | |
| 10 mM | 0.1877 mL | 0.9385 mL | 1.8771 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
